Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: DRUG: Metformin + Myocet + Cyclophosphamide|DRUG: Myocet + Cyclophosphamide
Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori